Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Investor Presentation (January 2025)
26 slides from Akari Therapeutics's investor presentation, Jan 13, 2025
Slide 1: Corporate Presentation January 2025
Corporate Presentation January 2025 NASDAQ: AKTX akaritx.com Next-Generation Precision Bi-Functional Antibody Drug Conjugates
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc
Slide 3: We Are Akari Therapeutics
WE ARE Akari Therapeutics is an innovative targeted oncology company built on next-generation ADCs and a novel discovery engine AKARI THERAPEUTICS
Slide 4: Innovative Precision Antibody Drug Conjugates for the Treatment of Cancer
Innovative Precision Antibody Drug Conjugates (ADCs) for the Treatment of Cancer Why Akari Discovery platform allows for generation of novel Bi-Functional ADC candidates with spliceosome inhibitor payload Significant advantages over current TROP2 ADCs observed in multiple preclinical models: Superio
Slide 5: Global ADC Market Expected to Grow Significantly
Global ADC Market Expected to Grow Significantly1 Antibody drug conjugates market. Market.us. (2023, November 3). https://market.us/report/antibody-drug-conjugates-market/ 2023 Sales from Approved ADCs ADCs Have Revolutionized Cancer Therapy, But Have Some Shortcomings Solid Tumors Liquid Tumors Pro
Slide 6: Bi-Functional ADC Platform Targeting Cancer
Bi-Functional ADC Platform Targeting Cancer Antibody Targeting Clinically Validated TROP2 Receptor on Tumor Cells Linker Connects Anti-Tumor Payload to Targeting Antibody Payload Differentiated Novel PH1 Payload Disrupts Normal RNA Splicing, Leading to Cancer Cell Apoptosis Highly Selective Cancer C
Slide 7: Next-Generation Precision ADC Pipeline
Next-Generation Precision ADC Pipeline Program Indication Discovery Preclinical Clinical Highlights AKTX-101 (TROP2 PH1 ADC) ADC with Novel Payload Solid Tumors Novel Payload: PH1 Advancing IND-enabling preclinical studies Pursue licensing / strategic partnership AKTX-102 (Undisclosed Target) ADC wi
Slide 8: Akari Platform Technology Can Fuel a Pipeline
Application Targeting Antibody Proprietary Linkers Anti-Cancer Payload Lung Cancer CD20 Lys-L92 Colorectal Cancer Nectin-4 Lys-L91 Prostate Cancer HER2 LYS-L2 PH5 Breast Cancer TROP2 LYS-L22 PH1 Stomach Cancer HER3 Cys-L18 PH6 Pancreatic Cancer DLL3 Cys-L11 Ovarian Cancer ROR1 Cys-L94 Liver Cancer A
Slide 9: Novel PH1 Payload: Superior Activity Across Tumor Types and Targets
Novel PH1 Payload: Superior Activity With Potent Effect Across Various Tumors Types and Targets Using Platform Technology Her2 Gastric Her2High Breast Her2Low Trop2 Gastric TropHigh Bladder Trop2Heterogenous NSCLC TargetMedium Pancreatic Trop2High In Vitro Studies Performed at Lower PH1 Drug Dose (L
Slide 10: AKTX-101: Novel Payload is a Spliceosome Inhibitor
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects
Slide 11: AKTX-101: Direct Tumor Cell Cytotoxicity and Generation of Neoantigens
Antibody receptor complex is internalized by endocytosis. PH1 ADC binds to the target receptor. 1 Lysosome fuses with endosome. Lysosomal enzymes degrade the ADC, releasing the active payload species. PH1 disrupts alternative splicing in the tumor cell, a fundamental process for tumor transformation
Slide 12: Immune response to payload-induced neoepitopes
Active payload kills majority of target cells Stimulates payload-induced neoepitopes in survivors Resistant cells killed by immune response TARGET CELL T cells recognize neoantigens and become primed for killing tumor cells Synergy with checkpoint inhibitor therapies that further enhance immune resp
Slide 13: PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge
PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge with Tumor Cells Potent Synergy With Checkpoint Inhibitor Has Potential to Cure Colorectal Tumors PH1 Induced Tumor-Specific Immune Memory Tumor-regressed MC38-hHer2 ADC Doses Rechallenge MC38-hHer2 B16-F10 ADC Treatment and Su
Slide 14: AKTX-101: Novel Payload is a Spliceosome Inhibitor
Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects Accumulation of mis-spliced proteins generates neoantigens that can be recognized by th
Slide 15: AKTX-101: Demonstrated Reduced Off-Target Toxicity in Preclinical Study
AKTX-101: Demonstrated Reduced Off-Target Toxicity in Preclinical Study Normal Human Fibroblasts TROP2none Limited effect on Normal Human Fibroblasts, an example of off-target toxicity of Trodelvy® No cytotoxicity against normal human fibroblasts as observed in FIC (Attributed to superior linker sta
Slide 16: AKTX-101: Novel Payload is a Spliceosome Inhibitor
Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects Accumulation of mis-spliced proteins generates neoantigens that can be recognized by th
Slide 17: AKTX-101: Shown to Avoid Development of Resistance in Preclinical Study
AKTX-101: Shown to Avoid Development of Resistance in Preclinical Study PH1 potency unaffected by overexpression of multidrug resistance (MDR) transporters 200X higher MMAE concentration required to kill cells overexpressing MDRs; inhibition of MDR 1/2 by elacridar restores MMAE potency PH1 Payload
Slide 18: AKTX-101: Novel Payload is a Spliceosome Inhibitor
Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects Accumulation of mis-spliced proteins generates neoantigens that can be recognized by th
Slide 19: AKTX-101 Anti-Tumor Activity and Improved Survival With Standard of Care
AKTX-101 Demonstrated Anti-Tumor Activity and Improved Overall Survival in Combination With Standard of Care I/O Note: Patent pending so exact model, I/O drug and dosing not disclosed Superior Overall Survival Combination With IO Superior Anti-Tumor Efficacy In Combination With IO Mouse Bladder Syng
Slide 20: Recent ADC Licensing Deals
Licensee Licensor Phase Asset Target Date Deal Type Upfront Payment Total Deal Highlights Preclinical ADC Technologies Undisclosed 1/2025 Licensing Undisclosed Undisclosed upfront payment and up to $1.3 billion, plus additional royalty payments on net sales of resulting products Preclinical AVZO-141
Slide 21: Proven Management Team
Proven Management Team Samir R. Patel, MD Chief Executive Officer Serial entrepreneur with more than 20 years of experience in life sciences with multiple successful exits Torsten Hombeck, PhD Chief Financial Officer Seasoned executive with over 20 years of expertise in finance, capital markets and
Slide 22: Highly Experienced, Involved, Knowledgeable Board
Highly Experienced, Involved, Knowledgeable Board to Help Steer Strategy and Execution Hoyoung Huh, MD, PhD Chairman Founder of Peak Bio Inc. and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015 Samir R. Patel, MD Chief Executive Officer CEO since Dec
Slide 23: Upcoming Expected Value Driving Milestones
Upcoming Expected Value Driving Milestones Building a Next-Generation Precision Bi-Functional ADC Platform Legacy Pipeline Assets Present anticipated PH1 Payload Preclinical Data at Scientific Conference Complete additional IND-enabling preclinical studies for AKTX-101 Generate additional validating
Slide 24: Legacy Pipeline Assets Beyond ADC Platform
Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Global Market Opportunity PAS-Nomacopan Long-Acting Complement C5 & Leukotriene B4 Inhibitor for Eye Geographic Atrophy $23 Billion1 PHP-303 Neutrophil Elastase Inhibitor Alpha-1 Antitrypsin Deficiency $1.4 Billion2 Acute Respiratory D
Slide 25: Why Now
Why Now Next-Generation Precision Antibody Drug Conjugates (ADC) Candidates for the Treatment of Cancer Innovative Bi-Functional ADC Platform Technology Customizable Targets by Tumor, Novel Payloads, Unique Linkers to Generate a Pipeline of Superior ADCs for Out-Licensing Opportunities AKTX-101 (TR
Slide 26: Investor Relations
Investor Relations JTC Team aktx@jtcir.com (908) 824-0775 Next-Generation Precision Bi-Functional Antibody Drug Conjugates
Akari Therapeutics — Investor Presentation (January 2025) on 6ix